At a glance
ClinicalIndex Comparison Record- ✓Age 65 years or older
- ✓Clinical diagnosis of Alzheimer's disease with MoCA score 10-20 and CDR = 1
- ✓On stable dose of cholinesterase inhibitors for at least 3 months
- ✓BMI 19-35 kg/m²
- ✕Myocardial infarction, angina, stroke, or transient ischemic attack within past 6 months
- ✕QT interval >440 ms on ECG
- ✕Chronic heart failure
- ✕Coagulation disorders
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
In Brief
A Phase 2 clinical trial evaluating Dasatinib + Quercetin for Alzheimer Disease. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) \[D+Q\], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans with other chronic illnesses and in Alzheimer's mice models. The study team want to know if this combination of medications will reach the brain in order to evaluate if this intervention may be effective for treating AD symptoms in future studies. This is also known as a "proof of concept" study.
Study Details
Timeline
Interventions
Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)